This modulation decreases IL-10, TGF-β, and IL-17A levels in the serum of liver cancer mice (p < 0.01), while increasing IL-2 and IFN-γ levels (p < 0.01) [8]. This evidence concerns the gene TGFB1 and liver cancer.